Close Menu

NEW YORK (GenomeWeb) – Aldatu Biosciences has been awarded direct-to-Phase II Small Business Innovation Research funding to develop its quantitative PCR-enabling technology into test kits to detect genes conferring resistance to certain HIV treatments. 

The funding is from the National Institute of Allergy and Infectious Diseases and totals approximately $3 million over three years. It will be used to adapt the firm's pan-degenerate amplification and adaptation (PANDAA) method for reagent and product development to diagnose HIV resistance to protease inhibitor therapeutics. 

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.